(Q51989059)

19 April 2018

title

Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. (English)

1 reference

19 April 2018

author

Andrew James McMichael

3

object named as

Andrew J McMichael

1 reference

19 April 2018

author name string

Marie J Estcourt

1

1 reference

19 April 2018

Sven Létourneau

2

1 reference

19 April 2018

Tomás Hanke

4

1 reference

19 April 2018

language of work or name

English

0 references

publication date

1 September 2005

1 reference

19 April 2018

European Journal of Immunology

published in

1 reference

19 April 2018

volume

35

1 reference

19 April 2018

page(s)

2532-2540

1 reference

19 April 2018

issue

9

1 reference

19 April 2018

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

Cutting edge: rapid in vivo killing by memory CD8 T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

Organ-specific CD4+ T cell response during Listeria monocytogenes infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

21 January 2018

HIV vaccines 1983-2003.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Studies on poxvirus infections in irradiated animals

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Virus-specific CD8+ T-cell memory determined by clonal burst size

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection?

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Cytomegalovirus (CMV)-specific cellular immune responses.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

The role of programming in memory T-cell development

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Molecular and functional profiling of memory CD8 T cell differentiation.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Estimating the precursor frequency of naive antigen-specific CD8 T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Response of naïve and memory CD8+ T cells to antigen stimulation in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Systemic T cell expansion during localized viral infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Virus-specific CD8+ T cells in primary and secondary influenza pneumonia

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

In vivo proliferation of naïve and memory influenza-specific CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

In vivo compartmentalization of functionally distinct, rapidly responsive antigen-specific T-cell populations in DNA-immunized or Salmonella enterica serovar Typhimurium-infected mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

CD8+ T cells responding to influenza infection reach and persist at higher numbers than CD4+ T cells independently of precursor frequency

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Preferential localization of effector memory cells in nonlymphoid tissue

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Visualizing the generation of memory CD4 T cells in the whole body

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Role of viral factor E3L in modified vaccinia virus ankara infection of human HeLa Cells: regulation of the virus life cycle and identification of differentially expressed host genes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Toll-like receptor 3 promotes cross-priming to virus-infected cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

DNA vaccines against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Progress in DNA-based heterologous prime-boost immunization strategies for malaria

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Jump-starting the immune system: prime-boosting comes of age.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Exposing the immunology of naked DNA vaccines.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Gene vaccination with naked plasmid DNA: mechanism of CTL priming

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Massive expansion of antigen-specific CD8+ T cells during an acute virus infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535184

7 January 2021

Identifiers

DOI

10.1002/EJI.200535184

1 reference

19 April 2018

PubMed ID

16144036

1 reference

19 April 2018